177 related articles for article (PubMed ID: 31697431)
1. Histopathology-guided mass spectrometry differentiates benign nevi from malignant melanoma.
Lazova R; Smoot K; Anderson H; Powell MJ; Rosenberg AS; Rongioletti F; Pilloni L; D'Hallewin S; Gueorguieva R; Tantcheva-Poór I; Obadofin O; Camacho C; Hsi A; Kluger HH; Fadare O; Seeley EH
J Cutan Pathol; 2020 Mar; 47(3):226-240. PubMed ID: 31697431
[TBL] [Abstract][Full Text] [Related]
2. Imaging mass spectrometry--a new and promising method to differentiate Spitz nevi from Spitzoid malignant melanomas.
Lazova R; Seeley EH; Keenan M; Gueorguieva R; Caprioli RM
Am J Dermatopathol; 2012 Feb; 34(1):82-90. PubMed ID: 22197864
[TBL] [Abstract][Full Text] [Related]
3. Proteomic Mass Spectrometry Imaging for Skin Cancer Diagnosis.
Lazova R; Seeley EH
Dermatol Clin; 2017 Oct; 35(4):513-519. PubMed ID: 28886807
[TBL] [Abstract][Full Text] [Related]
4. Mass Spectrometry Imaging Can Distinguish on a Proteomic Level Between Proliferative Nodules Within a Benign Congenital Nevus and Malignant Melanoma.
Lazova R; Yang Z; El Habr C; Lim Y; Choate KA; Seeley EH; Caprioli RM; Yangqun L
Am J Dermatopathol; 2017 Sep; 39(9):689-695. PubMed ID: 28248717
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements.
Chandler WM; Rowe LR; Florell SR; Jahromi MS; Schiffman JD; South ST
Arch Pathol Lab Med; 2012 Aug; 136(8):947-55. PubMed ID: 22849744
[TBL] [Abstract][Full Text] [Related]
6. Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue.
Koh SS; Opel ML; Wei JP; Yau K; Shah R; Gorre ME; Whitman E; Shitabata PK; Tao Y; Cochran AJ; Abrishami P; Binder SW
Mod Pathol; 2009 Apr; 22(4):538-46. PubMed ID: 19270649
[TBL] [Abstract][Full Text] [Related]
7. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma.
Clarke LE; Warf MB; Flake DD; Hartman AR; Tahan S; Shea CR; Gerami P; Messina J; Florell SR; Wenstrup RJ; Rushton K; Roundy KM; Rock C; Roa B; Kolquist KA; Gutin A; Billings S; Leachman S
J Cutan Pathol; 2015 Apr; 42(4):244-52. PubMed ID: 25727210
[TBL] [Abstract][Full Text] [Related]
8. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.
van Dijk MC; Bernsen MR; Ruiter DJ
Am J Surg Pathol; 2005 Sep; 29(9):1145-51. PubMed ID: 16096402
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Histopathologic Characteristics of Melanocytic Lesions on the Volar Skin Without Typical Dermoscopic Patterns.
Mikoshiba Y; Minagawa A; Koga H; Yokokawa Y; Uhara H; Okuyama R
JAMA Dermatol; 2019 May; 155(5):578-584. PubMed ID: 30865233
[TBL] [Abstract][Full Text] [Related]
10. Digital computer analysis of dermatoscopical images of 260 melanocytic skin lesions; perimeter/area ratio for the differentiation between malignant melanomas and melanocytic nevi.
Fikrle T; Pizinger K
J Eur Acad Dermatol Venereol; 2007 Jan; 21(1):48-55. PubMed ID: 17207167
[TBL] [Abstract][Full Text] [Related]
11. Fascin expression in melanocytic lesions of the skin.
YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin.
Gerami P; Alsobrook JP; Palmer TJ; Robin HS
J Am Acad Dermatol; 2014 Aug; 71(2):237-44. PubMed ID: 24906614
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of COX-2 protein expression in melanocytic nevi in children].
Kubus M; Andrzejewska E; Nejc D; Kobos J; Taran K
Pol Merkur Lekarski; 2013 Aug; 35(206):82-4. PubMed ID: 24052986
[TBL] [Abstract][Full Text] [Related]
15. Potential diagnostic significance of HSP90, ACS/TMS1, and L-plastin in the identification of melanoma.
Strickler AG; Vasquez JG; Yates N; Ho J
Melanoma Res; 2014 Dec; 24(6):535-44. PubMed ID: 25191796
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of melanoma and benign nevi by fluorescence in-situ hybridization.
Hossain D; Qian J; Adupe J; Drewnowska K; Bostwick DG
Melanoma Res; 2011 Oct; 21(5):426-30. PubMed ID: 21900793
[TBL] [Abstract][Full Text] [Related]
17. Discrimination of benign common nevi from malignant melanoma lesions by use of features based on spectral properties of the wavelet transform.
Wiltgen M; Gerger A; Wagner C; Bergthaler P; Smolle J
Anal Quant Cytol Histol; 2003 Oct; 25(5):243-53. PubMed ID: 14603721
[TBL] [Abstract][Full Text] [Related]
18. [Thermographic examination of cutaneous melanocytic nevi].
Mikulska D
Ann Acad Med Stetin; 2009; 55(1):31-8; discussion 38. PubMed ID: 20349589
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases.
Vergier B; Prochazkova-Carlotti M; de la Fouchardière A; Cerroni L; Massi D; De Giorgi V; Bailly C; Wesselmann U; Karlseladze A; Avril MF; Jouary T; Merlio JP
Mod Pathol; 2011 May; 24(5):613-23. PubMed ID: 21151100
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness.
Bayer-Garner IB; Hough AJ; Smoller BR
Mod Pathol; 1999 Aug; 12(8):770-4. PubMed ID: 10463478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
